Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Innovative approaches in the management of gastrointestinal cancers
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Liquid biopsy in colorectal cancer – the time has come?
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
Benefits of immunotherapy in hepatocellular carcinoma are confirmed in Asian subpopulations
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
Hepatocellular carcinoma: apatinib after transarterial chemoembolisation prolongs PFS in a Chinese population
Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents
Serplulimab plus chemotherapy prolongs progression-free survival in PD-L1-positive oesophageal squamous cell carcinoma
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
Intensive follow-up and ctDNA screening may improve detection of early recurrence in CRC patients
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Potential new treatment options for metastatic colorectal cancer emerge from two studies
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
New data show promise of targeted treatment combinations in advanced KRAS G12C-mutated colorectal cancer
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer
Neoadjuvant immunotherapy in dMMR colon cancer - a paradigm shift?
Although not immediately practice-changing, impressive results from the NICHE-2 trial may open a way to a ‘watch and wait’ approach for some patients